Karim Fizazi, MD, PhD, joins the show to discuss the phase III TALAPRO-2 trial published in Nature on the use of first-line talazoparib with enzalutamide in patients with HRR-deficient metastatic castration-resistant prostate cancer. Dr. Fizazi is a medical oncologist at Gustave Roussy, and is a professor of oncology at the University of Paris-Saclay. ...
The Uromigos: Paper of the Month
Hear Thomas Powles, MD, and Brian Rini, MD, FASCO, share their picks for research paper of the month.
Advertisement
Dr. Rahul Aggarwal discusses his recent paper on a phase 1/2 study on Lu-177 with pembrolizumab for mCRPC.
Dr. Susan F. Slovin discusses her recent paper that examined abiraterone with and without cabazitaxel for mCRPC.
Dr. Meeks discusses expression-based subtypes for defining pathologic response to neoadjuvant ICIs in patients with MIBC.
Dr. Andrea Necchi describes his recent phase 2 study on the use of neoadjuvant pembrolizumab and nab-paclitaxel for MIBC.
The Uromigos chat with Axel Merseburger about his paper on continuing enzalutamide with docetaxel for the treatment of CRPC.
The Uromigos chat with Cora Sternberg on her paper on FGFR inhibition in advanced urothelial cancer.
John Kelly summarizes a recent paper published in JAMA that describes the benefits of robotic surgery versus open cystectomy.
Alex Wyatt joins The Uromigos to answer questions about ctDNA in prostate cancer and discuss his latest paper on that topic.
Syed Hussain and Sam Funt describe their studies on this topic.
Martin Stockler describes the ENZAMET trial, which shows mixed effects of enza on QOL in prostate cancer.
Yelena Janjigian describes ipi/nivo versus nivo chemo versus chemo in gastric cancer.
Elizabeth de Vries describes her paper on this topic published in Annals of Oncology.
Chad Tang discusses his oncology paper recently published in Lancet.
Dr. Samra Turajlic describes her paper on clear cell renal cell carcinoma.
Dr. Mike Atkins discusses the role of CTLA4 inhibition in RCC.
Dr. Tanya Dorff discusses the TALAPRO-1 study and the role of PARP inhibitors in prostate cancer.
Martin Eklund discusses his papers published in the New England Journal of Medicine and Lancet Oncology.
Dr. Eric Jonasch gives an overview of his paper published in Nature Medicine.
Dr. Petros Grivas discusses the accelerated approval of sacituzumab govitecan in bladder cancer.
Silke Gillessen discusses the back-to-back JCO papers on risk classification for germ cell cancer.
Dr. Joaquim Bellmunt describes this study, as well as adjuvant nivolumab and ctDNA in bladder cancer.
David McDermott describes back-to-back publications that examine pembrolizumab in clear cell and non-clear cell renal cancer.
Dr. Stephen Boorjian outlines his non-muscle invasive bladder cancer paper published in Lancet.
Dr. Kim Rathmell discusses this paper, which divides clear cell renal cancer into seven relevant subgroups.
Drs. Pam Sharma and Michiel Van Der Heijden discuss neoadjuvant PD(L)1 + CTLA4 inhibition in urothelial cancer.
Dr. James Eastham describes this study, which gives insight into perioperative treatments for high-risk prostate cancer.
Dr. Andrea Apolo talks about her phase 2 trial which shows activity for Cabozantinib in urothelial cancer.
Advertisement
